Arcus Biosciences, Inc. (RCUS)
Stock Price:
$24.05 USD
0.67 (2.87%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.37B |
| Revenue (ttm) |
15.00M |
| Net Income (ttm) |
-94.79M |
| Shares Out |
46.05M |
| EPS (ttm) |
-2.15 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$24.05 |
| Previous Close |
$23.38 |
| Change ($) |
0.67 |
| Change (%) |
2.87% |
| Day's Open |
23.61 |
| Day's Range |
22.52 - 24.14 |
| Day's Volume |
775,137 |
| 52-Week Range |
6.30 - 37.41 |
More Stats
| Market Cap |
1.37B |
| Enterprise Value |
1.21B |
| Earnings Date (est) |
Aug 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.05M |
| Float |
29.79M |
| EPS (basic) |
-2.15 |
| EPS (diluted) |
-2.15 |
| FCF / Share |
-2.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.67M |
| Short Ratio |
1.72 |
| Short % of Float |
5.11% |
| Beta |
1.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
91.46 |
| PB Ratio |
9.00 |
| Revenue |
15.00M |
| Operating Income |
-98.34M |
| Net Income |
-94.79M |
| Free Cash Flow |
-89.41M |
| Net Cash |
158.07M |
| Net Cash / Share |
2.77 |
| Gross Margin |
-423.21% |
| Operating Margin |
-655.57% |
| Profit Margin |
-632.00% |
| FCF Margin |
-596.04% |
| ROA |
-28.28% |
| ROE |
-52.34% |
| ROIC |
-81.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
8 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$38.00*
(58.00% upside)
Low
18.0
Current: 24.05
High
48.0
Target: 38.00
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 15.00 | 8.35 | 1.41 | - |
| Revenue Growth | 79.58% | 491.15% | - | - |
| Gross Profit | 15.00 | 8.35 | 1.41 | - |
| Operating Income | -88.71 | -54.86 | -53.44 | -18.18 |
| Net Income | -84.71 | -49.59 | -53.08 | -17.97 |
| Shares Outstanding | 43.83 | 34.62 | 1.83 | 0.86 |
| Earnings Per Share | -1.93 | -1.43 | -29.03 | -20.80 |
| Operating Cash Flow | -73.46 | -43.00 | -25.06 | -12.94 |
| Capital Expenditures | -1.93 | -3.74 | -5.51 | -4.10 |
| Free Cash Flow | -75.39 | -46.74 | -30.57 | -17.04 |
| Cash & Equivalents | 188 | 257 | 176 | 99.10 |
| Net Cash / Debt | 188 | 257 | 176 | 99.10 |
| Assets | 203 | 275 | 190 | 110 |
| Liabilities | 39.27 | 39.98 | 36.62 | 10.24 |
| Book Value | 164 | 235 | -72.33 | -19.99 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arcus Biosciences, Inc. |
| Country |
United States |
| Employees |
139 |
| CEO |
Terry J. Rosen |
Stock Information
| Ticker Symbol |
RCUS |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSE: RCUS |
| IPO Date |
March 15, 2018 |
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.